home.social

#amgen — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #amgen, aggregated by home.social.

fetched live
  1. The #avacopan story in #ANCA vasculitis is messy. IMHO #Amgen should be forced to withdraw & do another registrational trial. If not, they should be forced to do a PASS under a REMS.
    Finally was ava rolled out in Japan during a high #covid period -> VBS was due to virus+/-drug?

  2. The #avacopan story in #ANCA vasculitis is messy. IMHO #Amgen should be forced to withdraw & do another registrational trial. If not, they should be forced to do a PASS under a REMS. Finally was ava rolled out in Japan during a high #covid period -> VBS was due to virus+/-drug?

  3. #Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: biotech.industryexaminer.com/a #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews

  4. Today was a historic day for Thousand Oaks as Amgen broke ground on a $600 million R&D center here. This investment, one of the largest in Ventura County history, will speed development of new medicines by putting research and process development under one roof.

    As a global biotech leader Amgen can locate anywhere – but it chose Thousand Oaks because of our world-class workforce, excellent schools, abundant open space, and safe streets.

    I’m looking forward to the scientific breakthroughs this new center will bring, right here in Thousand Oaks!

    📷 1: Alex South; 📷 3: Josh Gray

    #amgen #biotech #research #pharma #thousandoaks #venturacounty

  5. 🚀 Big news in biotech!
    Amgen is investing $600M to build a cutting-edge center for science and innovation at its global HQ in Thousand Oaks, CA—driving advancements in biotechnology and healthcare solutions. 🌱

    Meanwhile, Enveric Biosciences is relocating its HQ to Cambridge, MA, strengthening one of the world’s most dynamic biotech hubs.

    👉 Full story: dlvr.it/TMw70V

    #Biotech #Innovation #Healthcare #Amgen #EnvericBiosciences #LifeSciences #EconDev

  6. GSK to sell remaining stake in Haleon, looks to raise $1.52B—US unveils proposal to ease restrictions on marijuana —FDA approves Amgen drug for small cell lung cancer --bit.ly/w28kSd #gsk #haleon #consumerhealth #pot #marijuana #medicalmarijuana #fda #amgen #smallcelllungcancer #lungcancer #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  7. ‘Next wave of IPOs’ will arrive in summer, predicts biotech-focused VC partner—Senate Finance Committee introduces legislation aimed at fixing drug shortages —Amgen 'encouraged' by weight-loss drug interim data, shares jump --bit.ly/w28kSd #funding #ipos #senate #medicare #drugshortages #amgen #weightloss #obesity #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma

  8. #Amgen to Buy #Horizon in #Biotech’s Biggest Deal of 2022 | BioSpace #pharma

    biospace.com/article/amgen-to- “The deal brings Horizon’s top asset, Tepezza (teprotumumab-trbw), into the Amgen fold. Tepezza won FDA approval in January 2020 for the treatment of thyroid eye disease, making it the first drug to notch a regulatory nod in this indication in the U.S.”

  9. 'Amgen is close to a deal to acquire Horizon Therapeutics in a transaction worth as much as $20bn, according to sources familiar with the matter, as a sell-off in healthcare stocks creates attractive targets.

    (...)

    The takeover would give Amgen access to Horizon’s pipeline of drugs for rare autoimmune and inflammatory diseases, including its blockbuster treatment Tepezza.'

    #DrugDiscovery #DrugDiscovery #Pharma #Amgen #Autoimmunity #Immunology

    ft.com/content/3cace2fc-406d-4

  10. This is shaping up to be a great year for our "#IP at the Supreme Court" series. We started with a bang with #Warhol, and now look forward to 3 events in spring on #patent enablement (#Amgen), #trademark's extraterritorial reach (#Hetronic), & now trademark expressive use (Jack Daniels).
    wcl.american.edu/impact/initia